Visiongain has published a new report: Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: Forecasts by Category (PD1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Cytokines Targets, Immuno Adjuvants, Immunomodulators), by PD1 Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo)), by PD-L1 Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), by CTLA-4 Inhibitors (Ipilimumab (Yervoy)), by Immuno Adjuvants (Imiquimod, Poly ICLC (Hiltonol)), by Immunomodulators (Pexidartinib (Turalio)), by Cytokines Targets (Aldesleukin, GM-CSF, Interferon Alfa-2a, Interferon Alfa-2b (Intron A®), Peginterferon alfa-2b (Sylatron®/PEGIntron®)), by Application (Lung Cancer Treatment, Renal Cancer Treatment, Blood Cancer Treatment, Bladder Cancer Treatment, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
Visiongain’s lead expert states: ‘The global checkpoint inhibitors for treating cancer market was valued at US$ 14187 million in 2020 and is projected to reach at a market value of US$ 63,420.2 million by 2031. Global checkpoint Inhibitor’s market is expected to grow at a CAGR of 14.6% during the forecast period 2021-2031. The market is estimated to grow at a CAGR of 14.5% in the first half period 2021-2026 and is projected to grow at CAGR of 14.7% in the other half period 2026-2031’.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/checkpoint-inhibitors-market-2021/#download_sampe_div
Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
The US Food and Drug Administration (FDA) has approved ICIs targeting separate molecules for use in humans so far. Ipilimumab, an anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody, was the first treatment for metastatic melanoma to be approved. Antibodies that block the inhibitory receptor programmed cell death 1 (PD-1) on T cells, which interacts with its ligands, PD-L1 and PD-L2, to thwart active T cell responses, make up the second class of ICIs.
Increasing Support from FDA in the Approval Procedures
Currently, the FDA has licensed two anti-PD-1 antibodies: pembrolizumab and nivolumab. These medications, such as ipilimumab, were initially approved to treat advanced-stage melanomas but have since been approved to treat a variety of cancers. The third group of FDA-approved ICIs is antibodies against PD-L1. Urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma are treated with three anti-PD-L1 antibodies: atezolizumab, durvalumab, and avelumab. Anti-PD-1 and anti-PD-L1 antibodies have outperformed anti-CTLA-4 antibodies in clinical trials due to a combination of superior clinical efficacy and tolerability.
How has COVID-19 had a significant impact on the Checkpoint Inhibitors for Treating Cancer Market?
The junction of coronavirus and cancer can be learnt a lot throughout the COVID-19 period. One area of concern has been whether immunotherapies enhance the risk of mortality in people with cancer who also have COVID-19 infection. Retrospective analyzes by Dr. Rogiers1 showed that immune-control inhibitor medication did not raise the risk of mortality in COVID-19 patients with cancer, according to the results of the multicenter. The mortality risk was 8 percent for individuals receiving immunological controls.
How this Report Will Benefit you?
Visiongain’s 610+ page report provides 448 tables and 447 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global checkpoint inhibitors for treating cancer market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Checkpoint Inhibitors for Treating Cancer. Get the financial analysis of the overall market and different segments and capture higher market share. We believe that high opportunity remains in this fast-growing checkpoint inhibitors for treating cancer market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits soon. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximize the productivity of the company.
What are the current market drivers?
New Products/Therapy Launch Are Gaining Tractions in the Global Market
To distinguish their product offerings, new entrants into the oncology industry may use a variety of strategies. One strategy is to be first-in-class with a novel mechanism of action (MOA); another is to focus on an indication with a strong unmet need, thus providing a valuable new therapeutic choice for patients with few choices.
Increasing Support from FDA in the Approval Procedures
Currently, the FDA has licensed two anti-PD-1 antibodies: pembrolizumab and nivolumab. These medications, such as ipilimumab, were initially approved to treat advanced-stage melanomas but have since been approved to treat a variety of cancers. The third group of FDA-approved ICIs is antibodies against PD-L1. Urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma are treated with three anti-PD-L1 antibodies: atezolizumab, durvalumab, and avelumab. Anti-PD-1 and anti-PD-L1 antibodies have outperformed anti-CTLA-4 antibodies in clinical trials due to a combination of superior clinical efficacy and tolerability.
Get Detailed TOC @ https://www.visiongain.com/report/checkpoint-inhibitors-market-2021/#download_sampe_div
Where are the market opportunities?
Unprecedented Advances in Cancer Immunotherapy
Blocking antibodies targeted to immune inhibitory receptors like CTLA-4, PD-1, and PD-L1 have been the most used immunotherapeutic agents in the last decade. Several antibodies and small molecules targeting other immune checkpoints, such as LAG3, TIGIT, TIM3, B7H3, CD39, CD73, the adenosine A2A receptor, and CD47, are in clinical research. The roles of CTLA-4, PD-1, and PD-L1 in inhibiting the immune response, as well as the roles of antibodies that block these molecules in cancer immunotherapy, are discussed in this section
Unmet Medical Needs
Despite the fact that the term "unmet medical need" has significant legislative consequences, no empirical study of its actual use has been done. To that end, researchers wanted to know the annual U.S. incidence, five-year survival, and number of NCCN-recommended regimens for indications that were identified in the literature as unmet medical needs.
Competitive Landscape
The major players operating in the checkpoint inhibitors for treating cancer market are A Seagen Inc.,Agenus Inc. (Agenus), Agilent Technologies, Inc., AbbVie Inc. (AbbVie), Xencor, Inc., Ono Pharmaceutical Co., Ltd., Sanofi SA, Eli Lilly and Company, Novartis AG, Pfizer Inc. (Pfizer), Roche Holding AG (Roche), Merck & Co., Inc., Incyte Corporation, Regeneron Pharmaceuticals, Inc., Amgen Inc., Bristol-Myers Squibb Company, Clovis Oncology, Inc., Heptares Therapeutics Ltd., These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch. For instance, in Jan 2021, Agenus Inc. an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer Market and leading companies. You will find data, trends, and predictions.
Find more Visiongain's research reports of Therapeutic Drugs Sector click on the following links:
- Cellular Immunotherapy Market
- Respiratory Drug Delivery Market
- Vaccine Drug Delivery Market
- Acute Kidney Injury Treatment Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.